Abstract | Objective: Method: Retrospective, monocentric study based on French Scleroderma Database in patients receiving mycophenolate mofetil who experienced a limited sampling strategy to estimate individual mycophenolic acid area under the curve plus two pulmonary function tests and skin evaluation after 1 month and 1 year. Efficacy criterions were variations of modified Rodnan skin score, forced vital capacity, and diffusing lung capacity for carbon monoxide at 1 year. Results: We included 52 patients; mean age was 49 years (range 17-79), and 36 (69%) were females. Fifty patients (96%) had skin sclerosis, 39 (75%) had diffuse skin involvement with a median modified Rodnan skin score of 14 (0-38). Thirty-eight (76%) had interstitial lung disease, with median forced vital capacity and diffusing lung capacity for carbon monoxide of 81% (37-127) and 56% (28-103) from predicted values, respectively. Twenty-five (51%) patients had pulmonary fibrosis. Mycophenolate mofetil was given for 10 months (0-173) at a median dose of 2000 mg/day (500-3000). In the entire population, no relationship was found between area under the curve and modified Rodnan skin score (p = 0.085), forced vital capacity (p = 0.80), or diffusing lung capacity for carbon monoxide (p = 0.72) variations at 1 year. Conclusion:
|
Authors | Paul Legendre, Benoit Blanchet, Raphael Porcher, Alice Bérezné, Marie Allard, Jonathan London, Benjamin Terrier, Pascal Cohen, Claire Le Jeunne, Luc Mouthon |
Journal | Journal of scleroderma and related disorders
(J Scleroderma Relat Disord)
Vol. 6
Issue 1
Pg. 87-95
(Feb 2021)
ISSN: 2397-1991 [Electronic] England |
PMID | 35382246
(Publication Type: Journal Article)
|
Copyright | © The Author(s) 2020. |